Tau Kit
Our SIMOA® Tau Kit is designed for the measurement of Tau in serum, human plasma and CSF. Click here to…
Posted on
ALZHEIMER’S AND DEMENTIA: THE JOURNAL OF THE ALZHEIMER’S ASSOCIATION | NOVEMBER 20, 2020
Fani L, Ahmad S, Ikram MK, Ghanbari M and Ikram MA.
Alzheimers Dement. 2020 Nov 20
DOI: https://doi.org/10.1002/alz.12212
We investigated how components of immunity relate to biomarkers of Alzheimer’s disease (AD) in plasma and explored the influence of AD genetic risk factors in the population‐based Rotterdam Study.
In 7397 persons, we calculated the granulocyte‐to‐lymphocyte ratio (GLR), platelet‐to‐lymphocyte ratio (PLR), and systemic immune‐inflammation index (SII). In 3615 of these persons, plasma amyloid‐beta (Aβ)42 and Aβ40 were measured. Next, we constructed an overall genetic risk score (GRS) based on genome‐wide significant variants, both including and excluding APOE ε4.
All innate immunity phenotypes were related to higher Aβ, most strongly with a doubling in GLR leading to a 1.9% higher Aβ42 (95% confidence interval [95% CI] 0.4 to 3.3%) and 3.2% higher Aβ40 (95% CI 2.0 to 4.3%). Higher AD GRS including APOE ε4 was associated with higher immunity markers.
Higher levels of immunity markers were associated with higher Aβ in plasma. Participants with a higher genetic predisposition to AD had higher immunity markers, where these effects were mainly driven by APOE ε4.
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…
Our SIMOA® Tau Kit is designed for the measurement of Tau in serum, human plasma and CSF. Click here to…
Amyloid Beta 42 (Aβ42) assays are SIMOA® assay kits for the measurement of the Aβ42 proteolytic product in human plasma.…
The AMYLOID BETA 40 (Aβ40) assays are SIMOA® assay kits for the measurement of the 40aa proteolytic product from the…
NF-LIGHT®, our Nfl assay, is an immunoassay kit for the ultra-sensitive measurement of neurofilament light levels in serum, plasma and…